Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
293M
-
Number of holders
-
138
-
Total 13F shares, excl. options
-
105M
-
Shares change
-
-9.83M
-
Total reported value, excl. options
-
$272M
-
Value change
-
-$30.3M
-
Put/Call ratio
-
1.98
-
Number of buys
-
70
-
Number of sells
-
-61
-
Price
-
$2.60
Significant Holders of AbCellera Biologics Inc. - Ordinary Shares (ABCL) as of Q3 2024
172 filings reported holding ABCL - AbCellera Biologics Inc. - Ordinary Shares as of Q3 2024.
AbCellera Biologics Inc. - Ordinary Shares (ABCL) has 138 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 105M shares
of 293M outstanding shares and own 35.73% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (27.5M shares), BAILLIE GIFFORD & CO (12.9M shares), Voya Investment Management LLC (10.6M shares), Prosight Management, LP (9.08M shares), UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (4.59M shares), ORBIMED ADVISORS LLC (4.18M shares), ArrowMark Colorado Holdings LLC (4.11M shares), BlackRock, Inc. (3.99M shares), RENAISSANCE TECHNOLOGIES LLC (2.95M shares), and TWO SIGMA INVESTMENTS, LP (2.53M shares).
This table shows the top 138 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.